The construction project of Xianyin Pharmaceutical Anti -New Crown Drug Production Base started

Zhonghong.com Jiangsu, June 8th. On June 8, 2022, the construction project of Xianmang Pharmaceutical (2096.HK) anti -new crown drug production base was officially started in Nanjing Jiangbei New District New Material Technology Park. The total investment of the project is 1.6 billion yuan, and the annual output value is expected to exceed 2 billion yuan. It takes only one month from the project to officially start. In the first phase of the plan, the annual output of anti -new crown and oral drugs can be produced by 100 tons, and the supply of tens of millions of people's anti -new crown oral drugs is of great significance to alleviate the pressure prevention pressure.

At the opening ceremony, Deputy Director Chen Yan of the Jiangbei New District Management Committee said: As a national new district, Jiangbei New District has always put independent innovation in the first place in the first place The first -time pharmaceutical industry and Jiangbei New District have been in the long time. We will accelerate our services and support the anti -new crown drug production base project. In a month, we set a record from the project to approval to the construction. We look forward to that the project can be put into production as soon as possible and achieve the goal of putting in advance.

Ren Jin Sheng, chairman The first phase of clinical research of the anti -new coronary virus candidate drug SIM0417 of the Chinese Academy of Sciences Shanghai Pharmaceutical Research Institute and Wuhan Virus Research Institute has ended, and is starting the second and third clinical trials, while actively striving to promote cooperation with overseas clinical centers. Today's project has started smoothly. Thanks to the government for their rapid response and support, it reflects the focus of the major strategic demand for the country's immunity. The production base will carry the SIM0417 raw medicine and preparation production tasks, and we will definitely go all out to submit a satisfactory answer to the country.

On May 16, 2022, the anti -new coronary virus candidate drug SIM0417 has obtained the clinical trial approval notice issued by the State Drug Administration It is intended to be used for exposure to the exposure of the confidential population exposed to the new crown detection.

On June 1, 2022, the First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital in Shandong Province) announced that it is for the safety of the safety of a single/after administration in healthy adults , Tolerance and pharmacokinetics I clinical studies, the last case of the last case and intra -hospital observation were completed in the development of the SIM0417 of the anti -epidemic drug project. At present, the observation of the first phase of the clinical research institute has ended.

- END -